Mendel Goldfinger, M.D.
< Back to Search Results

Mendel Goldfinger, M.D.


Accepts New Patients
Gender: Male
Language: English
Insurances Accepted View

Locations and Appointments



  • Lymphoma
  • Immunotherapy
  • Stem Cell Transplant
  • Non Hodgkin's Lymphoma
  • Hodgkin's Disease
  • Multiple Myeloma
  • Leukemia
  • Myelodysplastic Syndrome
  • Bone Marrow Disorder
  • Bleeding Disorder
  • Clotting Disorder
  • Anemia
  • Thrombocytopenia


Board Certifications

  • Internal Medicine
  • Hematology
  • Medical Oncology

Clinical & Academic Positions

  • Attending Physician - NewYork-Presbyterian/Brooklyn Methodist Hospital
  • Assistant Professor of Clinical Medicine - Weill Cornell Medical College, Cornell University

Education & Training

  • M.D., State University of New York at Buffalo, School of Medicine and Biomedical Sciences, 2011
  • B.S., Touro College, 2005


View Research

Personal Statement

Dr. William Osler said, “The good physician treats the disease; the great physician treats the patient who has the disease.” I am strong believer in individualizing treatment plans unique to each patient and I do this by learning and understanding the patient as a whole and the specifics of their disease. My ultimate goal is to provide the most positive clinical outcome to every patient.

My research interests are in developing novel immunotherapies to fight cancer and determining how to make cancer cells more susceptible to immunotherapy. I have a major interest in precision medicine in which treatment decisions are based on analyzing individual patient’s tumor mutations to find therapies which target mutations only found in cancer cells, while minimizing the risk of affecting other healthy cells. Another area of my research is focused on how to best dose anti-cancer therapies to optimize response while minimizing side effects and improving quality of life of our patients. I feel fortunate to have joined the faculty at Weill Cornell where I have the ability to work with world renowned researchers in all of these areas and collaborate with clinical research laboratories to advance the science in the war on cancer with the ultimate goal of curing cancer forever.


Prior to medical school, Dr. Goldfinger was a patient advocate in the New York community, where he voluntarily conducted medical referrals and patient advocacy for cancer patients. During this time, Dr. Goldfinger guided thousands of patients to cancer centers throughout the world to receive treatment. He was instrumental in enrolling numerous patients onto clinical trials where patients received novel therapies to which they otherwise would not have access. After seeing some patients achieve dramatic benefits from these therapies, Dr. Goldfinger decided to pursue a career in hematology and oncology clinical research with the goal of offering every cancer patient access to the newest therapies medicine can offer for their disease. He also learned from those experiences that each patient’s disease is unique and the need to narrowly tailor therapy for every patient.

Dr. Goldfinger is a graduate from University of Buffalo School of Medicine where he received his Doctor of Medicine (MD) degree. He did his internal medicine residency training at Montefiore Medical Center, Albert Einstein School of Medicine. He subsequently did a fellowship in Hematology, Medical Oncology and Stem Cell transplant at Rutgers Robert Wood Johnson Medical School.

Dr. Goldfinger has contributed to research in multiple tumor types. He conducted significant research in understanding tumor driver mutations, chemotherapy pharmacokinetics and how to optimize immunotherapy approaches. In his fellowship at the Rutgers Cancer Institute, he conducted research under the mentorship of Dr. Joseph Bertino and Dr. Shridar Ganesan. 

Dr. Goldfinger’s current research is focused on hematologic malignancies such as lymphoma, myeloma and leukemia, with a focus on chemotherapeutic dosing and better understanding of oncogenic driver mutations through next generation sequencing. He has written clinical trials assessing the best way to combine immunotherapy with chemotherapy, and has a special interest in learning how to best enhance the tumor immune microenvironment in order to make cancer cells more susceptible to immunotherapy.



Insurance Plans Accepted

For relevant information regarding accepted insurances, please contact this provider directly.

Honors and Awards

Honors and Awards

Outstanding Resident Award

Montefiore Medical Center

Awarded by the Internal Medicine Residency Program

June 2014


Intern of the Year Award

Montefiore Medical Center

Awarded by the Internal Medicine Residency Program

June 2012


Investigation in Neoplastic Diseases

Awarded by Harry E. and Loretta A. Jordan Foundation

University of Buffalo School of Medicine and Biomedical Science May 2011